Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Livzon Pharmaceutical Group ( (HK:1513) ) just unveiled an announcement.
Livzon Pharmaceutical Group Inc. has announced that its wholly-owned subsidiary, Livzon Group Limin Pharmaceutical Manufacturing Factory, received approval from the National Medical Products Administration for the market launch of its Progesterone Injection. This product, designed for supplementary progesterone therapy in assisted reproductive technology, offers a water-soluble formulation that enhances patient convenience and adherence by allowing self-administration and reducing adverse reactions.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. operates in the pharmaceutical industry, focusing on the development and manufacturing of chemical drugs. The company is primarily engaged in producing and marketing pharmaceutical products, with a particular emphasis on innovative drug formulations.
YTD Price Performance: -0.29%
Technical Sentiment Signal: Sell
Current Market Cap: $3.97B
Learn more about 1513 stock on TipRanks’ Stock Analysis page.